<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00721266</url>
  </required_header>
  <id_info>
    <org_study_id>BO21495</org_study_id>
    <secondary_id>2007-005939-28</secondary_id>
    <nct_id>NCT00721266</nct_id>
  </id_info>
  <brief_title>A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.</brief_title>
  <official_title>An Open Label, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Tumor Growth Control Rate of RO5083945, a Glycoengineered Antibody Against EGFR, in Patients With Metastatic and/or Locally Advanced Malignant EGFR+ Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics, maximum tolerated dose and anti-tumor activity
      of RO5083945 in patients with metastatic and/or locally advanced malignant EGFR+ solid
      tumors. In the first part of the study, groups of patients will be sequentially enrolled to
      receive ascending doses of RO5083945 administered weekly, every 2 weeks or every 3 weeks. The
      starting dose of 50mg weekly will be escalated in subsequent groups of patients after a
      successful assessment of the safety, tolerability and pharmacokinetics of the previous dose.
      In Part 2 of the study, patients with EGFR+ and mutant KRAS colorectal cancer will be
      enrolled, and will receive RO5083945 at the recommended dose and regimen identified in Part
      1. The anticipated time on study treatment is until disease progression, and the target
      sample size is &lt;100 individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters, and maximum tolerated dose (Part 1)</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor growth control rate (CR, PR, SD) (Part 2)</measure>
    <time_frame>Event driven</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AEs and laboratory parameters, pharmacodynamic parameters (Parts 1 and 2)</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity (ORR, DR, PFS) (Part 2)</measure>
    <time_frame>Event driven</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5083945</intervention_name>
    <description>Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients, &gt;=18 years of age;

          -  centrally confirmed EGFR expression in tumor tissue;

          -  radiologically measurable or clinically evaluable disease;

          -  last dose of systemic anti-neoplastic therapy or radiotherapy &gt;=28 days prior to start
             of study;

          -  histologically or cytologically confirmed advanced stage, primary or metastatic EGFR+
             solid tumors (Part 1);

          -  histologically or cytologically confirmed advanced stage, primary or metastatic EGFR+
             and mutant KRAS colorectal cancer (Part 2);

          -  not more than 2 previous cytotoxic regimens for metastatic disease (Part 2).

        Exclusion Criteria:

          -  history of grade 3-4 toxicity resulting from previous anti-EGFR treatment;

          -  known or suspected CNS metastases;

          -  wild type KRAS colorectal cancer (Part 2).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2008</study_first_submitted>
  <study_first_submitted_qc>July 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2008</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

